Lyell Immunopharma Inc
Company Profile
Business description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Contact
201 Haskins Way
South San FranciscoCA94080
USAT: +1 650 695-0677
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
stocks
Valuation looks stretched for ASX healthcare share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,291.30 | 23.50 | 0.25% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,493.55 | 261.66 | 0.50% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,315.92 | 241.12 | -0.98% |
| NASDAQ | 25,484.07 | 418.20 | 1.67% |
| Nikkei 225 | 61,248.59 | 789.01 | 1.31% |
| NZX 50 Index | 14,179.86 | 12.45 | 0.09% |
| S&P 500 | 7,623.99 | 103.06 | 1.37% |
| S&P/ASX 200 | 9,153.20 | 24.20 | 0.27% |
| SSE Composite Index | 3,680.64 | 16.92 | 0.46% |